Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin α(IIb)β(3) in mice and humans

The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases. However, a major adverse side effect of ibrutinib is bleeding, including major hemorrhages. The bleeding associated with ibrutinib...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Dobie, Gasim, Kuriri, Fahd A., Omar, Musab M. A., Alanazi, Fehaid, Gazwani, Ali M., Tang, Chloe P. S., Sze, Daniel Man-yuen, Handunnetti, Sasanka M., Tam, Constantine, Jackson, Denise E.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2019
Предметы:
Thrombosis and Hemostasis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929381/
https://ncbi.nlm.nih.gov/pubmed/31869418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000640
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы